For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
07/27/15Amgen Announces Webcast of 2015 Second Quarter Financial ResultsPrinter Friendly Version
07/24/15FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple MyelomaPrinter Friendly Version
07/23/15Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple MyelomaPrinter Friendly Version
07/21/15European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High CholesterolPrinter Friendly Version
07/16/15Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaPrinter Friendly Version
06/19/15Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic MigrainePrinter Friendly Version
06/18/15Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive CarePrinter Friendly Version
06/10/15Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High CholesterolPrinter Friendly Version
06/08/15Amgen To Present At The Goldman Sachs Global Healthcare ConferencePrinter Friendly Version
06/05/15Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular DiseasePrinter Friendly Version